Trial Profile

A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Entinostat (Primary)
Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; Inflammatory breast cancer; Male breast cancer
Focus Adverse reactions
Acronyms Breast49

Most Recent Events

06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
31 Oct 2022 Status changed from recruiting to completed.
12 Dec 2018 Planned End Date changed from 1 Sep 2028 to 15 Oct 2028.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com